KonoSuba: Fantastic Days Celebrates Its First Anniversary With a 4 Star Legendary Festival Event
15.9.2022 04:02:00 EEST | Business Wire | Press release
KonoSuba: Fantastic Days, Nexon’s free-to-play mobile RPG, kicks off a two week celebration in honor of the game’s first anniversary. After battling for the last twelve months to defeat the villainous Devil King, our diligent heroes have earned the right to celebrate in festival events featuring premium gifts and rewards!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005361/en/
#Nexon #NexonAmerica #KonoSuba (Graphic: Business Wire)
On top of the generous pre-registration bonuses offered earlier this month, and capping off a truly remarkable year in the world of Axel, KonoFans can expect a bounty of rewarding activities and gifts for their time spent in-game:
- 1st Anniversary Login Bonus (8/23 - 9/11): Free 10x Draw Ticket, up to 3000 Quartz, and more!
- New Main Quest and New Main Story (Part 2, Chapter 8)
-
New Story Event: “A Duet with This Crimson Demon Girl!”
- Players can experience Kazuma and Megumin's duet, "Bad Apple," during this event
- Participating in event missions allow you to get 3★ Lia (Dancing Announcer) for free!
-
1st Anniversary Ticket Draw (8/25 - 9/4):
- Tickets can be acquired from the 1st Anniversary Ticket Present event (8/16 - 8/29)
- Offers a chance to win 100,000 Quartz, 4★ Guaranteed Ticket, and more!
-
1st Anniversary Free 10x Recruit (8/23 - 9/3):
- Tickets can be acquired from 1st Anniversary related events/campaigns
- Offers a chance to get 1st Anniversary characters for free
-
1st Anniversary Legendary Adventurer Festival Recruit:
- Special Members
- 4★ Kazuma (Stage For Two)
- 4★ Megumin (Singing Sensation)
- Legendary Adventurer Festival Members
- 4★ Aqua (Legendary Adventurer)
- 4★ Darkness (Legendary Adventurer)
Based on the hit comedy anime series of the same name, KonoSuba: Fantastic Days was launched globally on August 19, 2021, on iOS and Android devices, after a successful release in Japan. The game focuses on a high school student (Kazuma) reincarnated to a fantasy world, where he is joined by a useless goddess (Aqua), an explosion fanatic (Megumin), and an unhinged crusader (Darkness) in their quest to fight the Devil King. Following the original storyline, the anime-based mobile title features brand new story content and exclusive heroes and heroines created specifically for the game. KonoFans have been able to battle as their favorite characters from the anime, all voiced by the original Japanese actors, including Jun Fukushima, Sora Amamiya, Rie Takahashi, and Ai Kayano.
Come celebrate in the wonderful, fantastical world of Axel!
KonoSuba: Fantastic Days is published by Nexon in partnership with KonoSuba publisher Kadokawa, and developed by Sumzap.
To stay up-to-date on KonoSuba: Fantastic Days, visit the Google Play or App Store page, and be sure to follow @PlayKonoSuba on Instagram and Twitter for the latest news!
Assets: Image Asset
Social Media: Twitch / Twitter / Instagram / Discord / Facebook
About KonoSuba: Fantastic Days konosuba.nexon.com
Based on the popular anime series “KonoSuba: God's Blessing on this Wonderful World!”, KonoSuba: Fantastic Days is a free-to-play character-collection RPG for iOS and Android. Featuring fan-favorite characters, including Kazuma Satou, Aqua, Megumin and Darkness, the game follows the storyline from the original novel and includes bespoke characters created exclusively for the game. Last year, the Japanese release of KonoSuba: Fantastic Days saw great success, garnering recognition from players and praise from the KonoSuba fan base.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005361/en/
Contact information
Brian Klotz
Nexon America
NA_pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom